Marker Therapeutics Inc

Marker Therapeutics Inc is a startup based in the United States. Brouky classifies it under Healthcare & Life Sciences.

Marker Therapeutics develops multi-antigen recognizing T cell therapies for treating blood cancers and solid tumors, with clinical-stage programs including the Phase 1 candidate MT-601 targeting lymphoma patients who relapsed or are ineligible for anti-CD19 CAR-T therapy.